CobaltTM and CromeTM
Next Generation Device Platform
Cobalt & Crome ICDs and CRT-Ds* redefine defibrillation therapy by combining proven technologies with personalized therapy to help save lives and improve outcomes.
Overview
CobaltTM and CromeTM
Exclusive iATP algorithm, heart failure risk stratification, tablet-based programming and app-based remote monitoring, extended longevity, and 40 J on all shocks.
Unmatched Feature Suite
Cobalt XTTM
Cobalt™ XT ICDs and CRT-Ds with BlueSync™ technology enable tablet-based programming and app-based remote monitoring. These devices include an automated anti-tachycardia pacing automated ATP algorithm and are compatible with a simplified heart failure risk stratification tool.
The Cobalt XT system is also approved for 1.5T and 3T MR Conditional use, when MR conditions for use are met.
CobaltTM
Cobalt™ ICDs and CRT-Ds with BlueSync technology enable tablet-based programming and app-based remote monitoring, and offer exclusive algorithms to manage atrial fibrillation (AF) patients.
The Cobalt system is also approved for 1.5T and 3T MR Conditional use, when MR conditions for use are met.
CromeTM
Crome™ ICDs and CRT-Ds with BlueSync technology enable tablet-based programming and app-based remote monitoring, and provide proven exclusive shock reduction algorithms.
The Crome system is also approved for 1.5T and 3T MR Conditional use, when MR conditions for use are met.
Listen to the experts
Watch case presentations and expert opinion on Cobalt™ and Crome™ devices.
Patient-centric design
Longevity improvements
Mean longevity projections based on CareLink™ patient data.†
Increased shock output
Option for 40 J energy delivery on all shocks, including the first.
40 J
Maximum programmed energy
40 J
Maximum delivered energy§
47 J
Maximum stored energy◊
Intrinsic ATP™ algorithm
Intrinsic ATP™ is the only automated and smart ventricular antitachycardia pacing (ATP) algorithm that provides individualized therapy in real time.
In the first real-world analysis of iATP in Cobalt XT devices, iATP demonstrated the highest fast VT shock avoidance success rate at 85%.
- 85% shocks avoided in the fast VT zone (<188 BPM)
- 90% iATP overall shock avoidance rate
Quantitative comparisons between different studies are significantly limited by differences in protocols, methods and patient populations.
Simplified programming
On/off
Individualized therapy
ATP designed for each VT
Real-time response
If VT is redetected, iATP automatically adjusts the next ATP sequence.
Streamlined connectivity
BlueSync™ technology
Next Generation Cobalt and Crome with BlueSync™ technology enable secure, wireless communication.
Tablet-based CareLink SmartSync™ device manager
Cobalt XT ICDs and CRT-Ds
MyCareLink Heart™ mobile app or MyCareLink Relay™ Home Communicator
CareLink network and the
Get Connected service
Streamlined workflows & heart failure management
TriageHF™ technology
TriageHF™¶ is a simplified, integrated heart failure risk assessment tool that alerts clinicians to clinically relevant changes in a patient’s status that may lead to a heart failure decompensation.
Simple risk stratification
High, medium, and low
Streamlined clinic management
TriageHF™-enabled clinics# can leverage the technology for all ICD & CRT patients with OptiVol™, with backward compatibility.
Automated clinic alerts
Automated notifications to enable clinical action.
Addressing AF
Discover Cobalt XT's full suite of algorithms to help detect, reduce, and respond to atrial fibrillation (AF).
System features & exclusive algorithms
Discover exclusive features and algorithms available in the Next Generation Device Platform.
Next Generation Devices
Medtronic Academy
Find additional feature information along with a variety of educational resources and tools.
† These values should not be interpreted as precise numbers. Individual patient results may vary based on their specific programming and experience.
‡ With AdaptivCRT™ programmed to BiV and LV.
§ Energy delivered at connector block into a 50 Ω ± 1% load.
◊ Energy stored at charge end on capacitor.
|| From ADVANCE III, using ATP during charging along with NID = 30/40 programming, ATP reduced shocked episodes by 52%.8
¶ TriageHF is not an alarm. The TriageHF assessment does not replace heart failure assessments in standard clinical practice. Medical treatment should not be modified remotely based solely on the TriageHF assessment. Interpretation of the TriageHF assessment requires clinical judgement by a medical professional. The TriageHF assessment should be used in conjunction with professional guidelines for patient management decisions.
# TriageHF requires clinic activation. Contact your local Medtronic sales representative for activation requirements
1. Medtronic Claria MRI™ Quad CRT-D SureScan™ & Amplia MRI™ Quad CRT-D SureScan™ Mean Projected Service Life based on U.S. CareLink™ transmission data as of January 2019; UC201802366 EN.
2. Medtronic Cobalt™ XT HF Quad MRI SureScan™ Model DTPA2QQ device manual.
3. Medtronic Evera MRI™ XT DR SureScan™ and Evera MRI™ S DR SureScan™ Mean Projected Service Life based on U.S. CareLink™ transmission data as of January 2019; UC201802366 EN.
4. Medtronic Cobalt™ XT DR ICD MRI SureScan™ Model DDPA2D4 device manual.
5. Medtronic Visia AF™ VR SureScan™ Mean Projected Service Life based on U.S. CareLink™ transmission data as of January 2019; UC201802366 EN.
6. Medtronic Cobalt™ XT VR ICD MRI SureScan™ Model DVPA2D4 device manual.
7. Swenson DJ, Taepke RT, Blauer JJE, et al. Direct comparison of a novel antitachycardia pacing algorithm against present methods using virtual patient modeling. Heart Rhythm. 2020;17(9):1602–1608.
8. Arenal A, Proclemer A, Kloppe A, et al. Different impact of long-detection interval and anti-tachycardia pacing in reducing unnecessary shocks: data from the ADVANCE III trial. Europace. 2016;18(11):1719–1725.
The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Medtronic is under license.